Oncology Central

IMpassion130: first positive Phase III immunotherapy study in TNBC

0
The Phase III IMpassion130 study has demonstrated that TECENTRIQ® (atezolizumab) plus chemotherapy Abraxane® (Nab-paclitaxel) significantly reduces the risk of disease worsening or death in individuals with metastatic or locally advanced triple negative breast cancer (TNBC).
To view restricted content, please:
Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.